Board of Directors​

Kung-Yee Liang, Ph.D.

Chairman

Tamon Tseng, LL.M.

Director

Wan-Fang Ting

Director

Howard S. Lee, Ph.D.

Independent Director

Ming-Chin Chen, Ph.D.

Independent Director

Chin-Ting Chiu

Independent Director

Organization and responsibilities of the Board of Directors

The Board of Directors of OBI Pharma, Inc. is composed of six internationally renowned directors in various professional fields such as new drug research and development, biostatistics, law, international trade, accounting, etc., who are not only experienced and educated, but also have an international outlook, a broad vision, and insight into the current situation to ensure the direction and level of the company’s operation. 
Under the leadership of the Chairman, the Board of Directors of OBI Pharma, Inc. takes “integrity and social responsibility” as the core, and is responsible for counseling, supervising and evaluating the effective operation of the company’s management team and various departments. Internally, we strive to comply with laws and regulations and self-examine ourselves with the highest ethical standards, and set up various functional committees and audit offices such as audit and remuneration to implement the internal control system; Seek financial transparency and real-time disclosure of important information to protect the rights and interests of investors and fulfill corporate social responsibility. 

In addition, the external performance evaluation of the Board of Directors is conducted every three years, and the most recent performance evaluation of the Board of Directors was conducted by the China Corporate Governance Association, an external organization, for the period from January 1, 2021 to December 31, 2021. The performance evaluation of the board of directors of the organization is based on eight aspects, including the composition of the board of directors, guidance, delegation, supervision, communication, internal control and risk management, and self-discipline and other aspects of the board of directors. The evaluation method is based on questionnaires and company self-assessment, and the association reviews the relevant documents provided by the Company for review in writing, and interviews the chairman, independent directors and chief financial officer of the Company on February 14, 2022, to assist the Company in improving through the interaction and sharing of the evaluation process. The Board of Directors performance evaluation report was submitted on February 22, 2022, and the Company reported the results of the Board of Directors on March 18, 2022

Communication between independent directors and the head of internal audit and accountants

  1. The Company’s internal audit supervisor regularly communicates with the members of the Audit Committee the results of the audit report, and makes an internal audit report at the quarterly Audit Committee meeting, and reports to the members of the Audit Committee immediately if there is any special situation. There were no such special circumstances in the current year. The communication between the Audit Committee and the Head of Internal Audit of the Company is in good condition.
  2. The Company’s certified public accountants shall report the results of the audit of the financial statements and other communication matters required by relevant laws and regulations to the Audit Committee on a quarterly basis, and will report to the members of the Audit Committee immediately if there are any special circumstances, and there are no such special circumstances in the current year. The Company’s Audit Committee is in good communication with the certified public Accountants. 

Board Resolutions

2024-01-10 - The 16th of the 7th session
  1. Proposal for selling the property on Suite 8, Floor 14, Block F in Nangang Software Park.
2024-03-11 - The 17th of the 7th session
  1. Approval of the 2023 Annual Final Accounting Ledgers and Statements of the Company.
  2. Approval of the Acknowledgment of the 2023 Earnings Distribution Loss Off-setting.
  3. Approval of proposal for stopping the OBI-3424 phase II clinical trial inclusion, but continuing cooperation with other institutions on the OBI-3424 plan.
  4. Approval of the 2024 Operating Plan of the Company.
  5. Approval of proposal for Recognizing the Internal Control System Statement of 2023.
  6. Approval of proposal for partial amendments to the Articles of Incorporation of the Company.
  7. Approval of proposal for partial amendments to the Rules of Procedures for Board of Directors Meetings.
  8. Approval of proposal for partial amendments to the Organizational Rules for Audit Committee.
  9. Approval of proposal for amending the audit plan to subsidiaries of 2024.
  10. Approval of proposal of Release the Prohibition on directors from Participation in Competitive Business.
  11. Approval of proposal of Release the Prohibition on managers from Participation in Competitive Business.
  12. Approval of determining the time and place for accepting shareholder proposals.
  13. Approval of proposal for determining the date, place and agenda of the General Shareholders’ Meeting of 2024.
  14. Approval of proposal for remuneration for the Chairman of the Company.
  15. Approval of proposal for appointing the new Vice President, Clinical Operations Division, American Subsidiary.
  16. Approval of proposal for appointing the new Global Pharmaceutical & Legal Deputy General Manager of American subsidiary.
  17. Approval of proposal for incentive bonus distribution for fulfilling the company objectives in 2023.
  18. Approval of proposal for the register of the first issuance of employee stock option certificates in 2024.